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A bs t r ac t
Background

Many mutations that contribute to the pathogenesis of acute myeloid leukemia (AML)
are undefined. The relationships between patterns of mutations and epigenetic
phenotypes are not yet clear.
Methods

We analyzed the genomes of 200 clinically annotated adult cases of de novo AML,
using either whole-genome sequencing (50 cases) or whole-exome sequencing (150
cases), along with RNA and microRNA sequencing and DNA-methylation analysis.
Results

AML genomes have fewer mutations than most other adult cancers, with an average
of only 13 mutations found in genes. Of these, an average of 5 are in genes that are
recurrently mutated in AML. A total of 23 genes were significantly mutated, and
another 237 were mutated in two or more samples. Nearly all samples had at least
1 nonsynonymous mutation in one of nine categories of genes that are almost certainly relevant for pathogenesis, including transcription-factor fusions (18% of
cases), the gene encoding nucleophosmin (NPM1) (27%), tumor-suppressor genes
(16%), DNA-methylation–related genes (44%), signaling genes (59%), chromatinmodifying genes (30%), myeloid transcription-factor genes (22%), cohesin-complex
genes (13%), and spliceosome-complex genes (14%). Patterns of cooperation and
mutual exclusivity suggested strong biologic relationships among several of the
genes and categories.

The authors (members of the Cancer Genome Atlas Research Network) are listed
in the Appendix. Address reprint requests
to Dr. Timothy J. Ley at Washington University School of Medicine, Division of
Oncology, Stem Cell Biology Section,
Campus Box 8007, 660 S. Euclid Ave., St.
Louis, MO 63110, or at timley@wustl.
edu.
This article was published on May 1, 2013,
and updated on June 13, 2013, at NEJM.org.
N Engl J Med 2013;368:2059-74.
DOI: 10.1056/NEJMoa1301689
Copyright © 2013 Massachusetts Medical Society.

Conclusions

We identified at least one potential driver mutation in nearly all AML samples and
found that a complex interplay of genetic events contributes to AML pathogenesis
in individual patients. The databases from this study are widely available to serve
as a foundation for further investigations of AML pathogenesis, classification, and
risk stratification. (Funded by the National Institutes of Health.)
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T

he molecular pathogenesis of acute
myeloid leukemia (AML) has been studied
with the use of cytogenetic analysis for
more than three decades. Recurrent chromosomal structural variations are well established as
diagnostic and prognostic markers, suggesting
that acquired genetic abnormalities (i.e., somatic
mutations) have an essential role in pathogenesis.1,2 However, nearly 50% of AML samples have
a normal karyotype, and many of these genomes
lack structural abnormalities, even when assessed with high-density comparative genomic
hybridization or single-nucleotide polymorphism
(SNP) arrays3-5 (see Glossary). Targeted sequencing has identified recurrent mutations in FLT3,
NPM1, KIT, CEBPA, and TET2.6-8 Massively parallel
sequencing enabled the discovery of recurrent
mutations in DNMT3A9,10 and IDH1.11 Recent
studies have shown that many patients with AML
carry no mutations in any of the currently recognized driver genes associated with the pathogenesis of AML.8,12
Patients with a cytogenetic profile that is associated with a favorable risk (i.e., those with PMLRARA, RUNX1-RUNX1T1, or MYH11-CBFB fusions)
have relatively good outcomes with chemotherapybased consolidation regimens, whereas patients
with an unfavorable-risk profile (monosomy karyotype or complex alterations) require allogeneic
transplantation during the first remission to im-
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prove their prognosis.13,14 However, the majority
of patients with AML have an intermediate cytogenetic risk (most commonly, a normal karyotype); some of these patients do well with chemotherapeutic consolidation, but others have a
very poor outcome. For this reason, recent studies have focused on establishing new biomarkers
for better classification of intermediate risk.8,15,16
Newer classification algorithms incorporate FLT3,
NPM1, CEBPA, and KIT into standard-of-care testing. Even more recently, testing has revealed that
mutations in newly discovered AML genes (e.g.,
DNMT3A, IDH1/2, and TET2) may also provide
prognostic information for some patients with
an intermediate-risk profile.8,12,16 None of the
current classification schemes are entirely accurate, which suggests that a more complete understanding of the genetic and epigenetic changes that are relevant to the pathogenesis of AML
will be required for better classification of risk
and, ultimately, better approaches to therapy.

Me thods
Patients

We selected samples from 200 adults with de
novo AML to represent the major morphologic
and cytogenetic subtypes of AML.8,15,16 The characteristics of these patients are fully described in
Table 1, and in Tables S1 and S2, Figure S1, and

Glossary
Comparative genomic hybridization: An array-based method that permits comparison of DNA abundance throughout
the genome between two DNA samples to identify regions where DNA copies have been gained or lost.
DNA methylation: This generally refers to the addition of a methyl group to the 5-carbon of the pyrimidine ring of cytosine, usually pertaining to cytosines that precede a guanine residue in DNA (a CpG dinucleotide motif). DNA methylation of CpG-rich regions (CpG islands) is often associated with repression of nearby genes.
MicroRNA: A short regulatory form of RNA that binds to a target RNA and suppresses its translation or alters its stability.
Single-nucleotide polymorphism (SNP) array: A microarray-based assay system that allows for simultaneous measurement of nucleotide sequence of hundreds of thousands of SNPs throughout the genome in a DNA sample. Acquired
copy-number variants can sometimes be detected with SNP arrays by comparing signals from the tumor and normal samples obtained from the same individual.
Single-nucleotide variant (SNV): A difference in a DNA sequence at a single position in the genome, as compared with
the reference genome; each variant may represent either an inherited or an acquired (somatic) change. SNPs generally represent inherited changes only.
Variant-allele clusters: Groups of mutations with similar variant allele frequencies, defined by statistical approaches.
A large group of mutations with variant-allele frequencies of approximately 50% generally represents the founding
clone of that tumor.
Variant-allele frequency (VAF): The relative proportion of sequencing reads from a variant allele (i.e., somatic mutation)
in a tumor sample. The VAF can be used to estimate the fraction of cells within a sample that contain that variant.
For example, variant alleles with a VAF of 50% usually represent heterozygous somatic mutations that are present
in all cells within the sample. Variant alleles with lower VAFs are generally present in only a fraction of the cells in a
sample, which may represent subclones derived from the founding clone of a tumor.
Whole-exome sequencing: Sequencing of the coding regions, or exons, of an entire genome from a single individual.
Whole-genome sequencing: Determination of the primary nucleotide sequence of the entire genome from a single individual.
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the Materials section in the Supplementary Appendix, available with the full text of this article
at NEJM.org. A video describing AML and this
study is also available at NEJM.org.

plete list of data sets is provided in Table S4 in
the Supplementary Appendix. All data sets are
available through the Cancer Genome Atlas (TCGA)
data portal (https://tcga-data.nci.nih.gov/tcga).

Analytic Platforms

We performed whole-genome sequencing of the
primary tumor and matched normal skin samples from 50 patients (with data from 24 of these
patients reported previously17) and exome capture and sequencing for another 150 paired samples of AML tumor and skin (see Table S3 in the
Supplementary Appendix for coverage data for the
200 samples).
All 200 patients who were selected for this
study were enrolled in a single-institution tissuebanking protocol approved by the human studies committee at Washington University. Written
informed consent for whole-genome sequencing
was obtained from all study participants.
The samples, which were banked between November 2001 and March 2010, were selected from
a set of more than 400 samples to reflect a realworld distribution of subtypes. Sample inventory
and quality issues also had to be considered in
the selection process, since the samples were analyzed on several different platforms. We identified candidate somatic variants using several algorithms (see the Methods section in the
Supplementary Appendix), and all the variants for
the 200 samples were verified with the use of
hybridization capture–based methods and deep
digital sequencing.18 We performed RNA-expression profiling on the Affymetrix U133 Plus 2
platform for 197 samples, RNA sequencing for
179 samples, microRNA (miRNA) sequencing for
194 samples, Illumina Infinium HumanMethylation450 BeadChip profiling for 192 samples,
and Affymetrix SNP Array 6.0 for both tumor and
normal skin samples from all 200 patients. Data
sets were not completed for all samples on all
platforms because of assay failures and availability and quality issues for some samples. The com-

R e sult s

A video detailing
the findings of
this study is
available at
NEJM.org

Copy-Number Alterations

In most de novo AML samples with a cytogenetic
profile indicating intermediate or favorable risk,
we detected very few copy-number events on highresolution SNP arrays, as reported previously3
(Fig. S2 and Table S5 in the Supplementary Appendix). Unfavorable-risk samples had chromosomal copy-number alterations that were verified
on the SNP arrays, and many had additional, cytogenetically cryptic events. No samples contained
evidence of chromothripsis (a single genomic event
that results in focal losses and rearrangements in
multiple genomic regions).19 Details of these analyses are presented in the Materials section in the
Supplementary Appendix.
Mutations in Coding Sequences

We discovered 2315 somatic single-nucleotide variants (SNVs) and 270 small insertions and deletions
(indels) in coding (tier 1) regions of the genome,
with an average of 13 tier 1 mutations per sample
(range, 0 to 51) (see box, and Table S6 in the
Supplementary Appendix). We observed no recurring coding mutations in three samples, but
all contained well-recognized fusion events that
are known to initiate AML (NUP98-NSD1 in Patient
868231, MLL-MLLT3/AF9 in Patient 923966, and
MLL-MLLT10/AF10 in Patient 558395). Three outlier samples contained 51, 36, and 35 tier 1 mutations; none of these samples contained mutations
in known DNA-repair genes. Of the 2315 SNVs,
1539 (66%) were missense and 510 (22%) had no
translational consequences. Small indels accounted for 270 of the 2585 validated mutations
(10%); of these, 191 (71%) caused frameshifts.
Samples were stratified into 10 groups on the

Tiers of Variants
Somatic variants that are identified on whole-genome sequencing and other large-scale sequencing analyses are often categorized according to their likely effect on biologic function. In this study, the somatic variants were divided into four tiers.
Tier 1: Changes in the amino acid coding regions of annotated exons, consensus splice-site regions, and RNA genes
(including microRNAs).
Tier 2: Changes in highly conserved regions of the genome or regions with regulatory potential.
Tier 3: Changes in the nonrepetitive part of the genome that do not meet the criteria for tier 2.
Tier 4: Changes in the remainder of the genome.
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basis of the presence or absence of known recurring fusion events, cytogenetic-risk profile, or the
presence or absence of TP53 mutations (which were
strongly associated with an unfavorable cytogenetic risk) (Fig. 1A). We observed significant differences in the numbers of recurrent tier 1 mutations in some of these groups. Eleven samples
had MLL fusions; this group had the fewest recurrent tier 1 mutations, with a mean of 2.09, as
compared with a mean of 5.24 for all 200 samples (P = 0.002 after correction for multiple comparisons). This finding suggests that MLL fusions
require fewer cooperating mutations than other
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AML-initiating events. Similarly, 20 samples containing PML-RARA fusions had fewer recurrent
tier 1 mutations (mean, 3.25; P = 0.001). We observed a higher mean number of recurrent tier 1
mutations in 7 samples containing either RUNX1RUNX1T1 fusions (mean value, 7.85; P = 0.04) and
in 13 samples with a combination of a high-risk
cytogenetic profile and a TP53 mutation (mean,
7.00; P = 0.049). Larger sample sets will be required to confirm these observations.
A total of 260 genes had somatic mutations in
at least 2 of the 200 samples; in 154 of these
genes, more than one mutation was nonsynony-

Table 1. Characteristics of the 200 Patients.*
Characteristic

Value

Age at study entry — yr

55.0±16.1

Race or ethnic group — no. (%)†
White

178 (89)

Black

15 (8)

Other

7 (4)

Male sex — no. (%)

108 (54)

Bone marrow blasts at diagnosis — %

69.3±19.1

Normal cytogenetic profile — no./total no. (%)

92/195 (47)

White-cell count at diagnosis — per mm3
Mean

36,300±48,500

Median

16,200

Cytogenetic risk group — no. (%)
Favorable

37 (18)

Intermediate

115 (58)

Unfavorable

43 (22)

Missing data

5 (2)

AML FAB subtype — no. (%)
AML with minimal maturation: M0

19 (10)

AML without maturation: M1

46 (23)

AML with maturation: M2

44 (22)

Acute promyelocytic leukemia: M3

20 (10)

Acute myelomonocytic leukemia: M4

41 (20)

Acute monoblastic or monocytic leukemia: M5

22 (11)

Acute erythroid leukemia: M6

3 (2)

Acute megakaryoblastic leukemia: M7

3 (2)

Other subtype

2 (1)

Immunophenotype — no./total no. (%)
CD13+

2062

140/185 (76)

CD33+

160/198 (81)

CD34+

123/199 (62)

CD117+

174/185 (94)
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Table 1. (Continued.)
Characteristic

Value

Mutation — no./total no. (%)
NPM1

54/200 (27)

FLT3

56/200 (28)

DNMT3A

51/200 (26)

IDH1 or IDH2

39/200 (20)

NRAS or KRAS

23/200 (12)

RUNX1

19/200 (10)

TET2

17/200 (8)

TP53

16/200 (8)

CEBPA

13/200 (6)

WT1

12/200 (6)
9/200 (4)

PTPN11

8/200 (4)

KIT
Loss of 5 or del(5q)

16/195 (8)

Loss of 7 or del(7q)

20/195 (10)

11q23

7/195 (4)

t(15;17)

18/195 (9)

t(8;21)

7/195 (4)

inv(16)

12/195 (6)

* Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. AML denotes acute myeloid
leukemia, and FAB French–American–British classification.
† Race or ethnic group was self-reported.

mous. An additional 1623 genes were found to
have a validated tier 1 mutation in one sample.
Using the significantly mutated gene (SMG) test
in the Mutational Significance in Cancer (MuSiC)
suite of tools,20 we identified 23 genes with a
higher-than-expected mutation prevalence (false
discovery rate, <0.05), including genes that are
well established as being relevant to AML pathogenesis (e.g., DNMT3A, FLT3, NPM1, IDH1, IDH2,
and CEBPA), along with genes that have only recently been implicated in AML pathogenesis, including U2AF1, EZH2, SMC1A, and SMC3 (Fig. 1B,
and Table S7 in the Supplementary Appendix).
We also identified and verified all variants in
noncoding regions in the 50 sample pairs that we
analyzed using whole-genome sequencing. After
the exclusion of 1 tumor sample, from Patient
817156, that had a high level of AML tumor cells
(36%) in the skin sample (Table S1 in the Supplementary Appendix), the median number of noncoding mutations in tumor samples was 394,
ranging from 68 to 1298. There was a strong
correlation between the number of coding and
n engl j med 368;22

noncoding mutations in each genome (Pearson’s
correlation coefficient, 0.78), suggesting that most
of the mutations were randomly distributed
throughout each genome. Most mutations in AML
genomes are probably background events that
occurred in hematopoietic stem cells before the
initiating event occurred; the clonal expansion
of these cells captures their mutational history,
as reportedly previously.17 This is also the reason
why nearly all mutations in AML genomes are
present in nearly all the cells in each sample.17
The results of an analysis of recurrently mutated
regions in tiers 2 and 3 (nongenic regions11) are
presented in Table S8 in the Supplementary Appendix, as are data for mitochondrial variants
(Table S9 in the Supplementary Appendix); the
relevance of these events to pathogenesis is unclear.
Using deep digital sequencing, we verified all
tier 2 and 3 variants that were discovered with the
use of whole-genome sequencing. This provided a
large number of sites for variant allele frequency
(VAF)–based cluster analysis, which allowed us to
nejm.org
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Figure 1. Characterization of Mutations.
Panel A shows the numbers of verified, recurrent tier 1 mutations in each of 200 samples obtained from patients with AML, organized
according to important cytogenetic and mutational findings. For each set of data, the middle horizontal line indicates the mean, and the
shaded area indicates ±1 SD. P values are shown for the groups that had significant differences from the mean number of recurrent tier 1
mutations in all samples. NK denotes normal karyotype. Panel B shows significantly mutated genes, as identified by the MuSiC analysis
suite,20 and the number of samples with each mutation. Panel C shows the number of discrete clusters of mutations with distinct variant
allele frequencies (VAFs) for each of 50 samples that underwent whole-genome sequencing. Each discrete VAF cluster represents a founding clone or a subclone derived from it.17,18 Samples with one clone have only a founding clone, those with two clones have a founding
clone and one subclone, those with three clones have a founding clone and two subclones, and so forth. Exome sequencing defined too
few mutations to accurately define subclones. Each sample contained evidence of a single founding clone, and most had one or more
subclones derived from the founding clone. The French–American–British (FAB) subtypes of the samples are designated. (See Table 1
for FAB subtypes of AML.)

define the clonal composition of each tumor.17,18
More than half the tumors contained both a
founding clone (the clone with the highest VAF
values) and at least one subclone; we were able to
identify as many as three independent subclones
in one tumor sample (Fig. 1C, and Table S1 in the
2064
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Supplementary Appendix). The coverage provided
by whole-genome sequencing in this study (mean,
30.54×) limited the power to detect small subclones with VAFs of less than 10% (Fig. S3A in
the Supplementary Appendix). Exome sequencing
produced a higher level of coverage for the tarnejm.org

may 30, 2013

The New England Journal of Medicine
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on March 24, 2014. For personal use only. No other uses without permission.
Copyright © 2013 Massachusetts Medical Society. All rights reserved.

Genomic landscapes of Acute Myeloid Leukemia

geted sequences (mean, 167.50×), slightly increasing our ability to detect mutations with VAFs of
less than 10%. However, the difference between
the number of tier 1 mutations detected with
whole-genome sequencing (14.5 per sample) and
the number detected with exome sequencing
(12.7 per sample) was not significant (P = 0.17)
(Table S6 in the Supplementary Appendix). The
mutational spectrum of all validated SNVs for all
200 samples is shown in Figure S3B in the Supplementary Appendix; transitions were the most common mutation type, as reported previously.17,18

Germline Variants

Expression of Mutant Alleles

We used complementary approaches to identify
combinations of mutations in the samples; for
this analysis, we considered only nonsynonymous mutations (Fig. 2). Using the HotNet algorithm,27 we identified six subnetworks of a genome-scale protein–protein interaction network
that had significant mutations (P<0.001). These
included portions of known pathways and protein complexes, including the cohesin complex17
(Fig. S7 in the Supplementary Appendix).
We grouped mutations into larger sets or pathways and examined patterns of mutual exclusivity and co-occurrence between these groups. Of
200 samples, 199 (>99%) contained at least one
mutation in one of nine categories that were
defined according to biologic function and that
have a putative role in AML pathogenesis: transcription-factor fusions (18% of cases), the gene
encoding nucleophosmin (NPM1) (27%), tumorsuppressor genes (16%), DNA-methylation–related
genes (44%), activated signaling genes (59%),
chromatin-modifying genes (30%), myeloid transcription-factor genes (22%), cohesin-complex
genes (13%), and spliceosome-complex genes (14%)
(Fig. 2, and Fig. S8 in the Supplementary Appendix). For all genes that had mutations in only a
small number of samples, the pathophysiological
relevance of the events will require further validation. FLT3 mutations were identified in 56 samples, and an additional 62 samples were found
to have mutations in genes encoding other kinases, phosphatases, or RAS family proteins
(Fig. S9 in the Supplementary Appendix). However, most of these genes contained mutations
in only 1 to 3 samples (with the exception of KIT,
KRAS, NRAS, and PTPN11). In total, 59% of samples had a mutation in a gene encoding a signaling protein.
To more fully assess patterns of mutual exclu-

Analysis of RNA sequences revealed allelic bias for
mutations in several genes. We observed increased
or exclusive expression of the mutant DNMT3A,
RUNX1, PHF6, and TP53 in several cases (Fig. S4A
through S4F in the Supplementary Appendix).
Loss of heterozygosity or partial uniparental disomy explained the enrichment of mutant allele
expression in most samples; epigenetic modifications (e.g., altered patterns of DNA or histone
methylation) may be responsible for the rest.
MiRNA

Variants

We identified somatic SNVs in miRNA genes in
7 of 200 samples (4%) (Table S10 in the Supplementary Appendix). Of these 7 samples, 4 had
mutations in miR-142 that were localized to the
seed region of the mature strand (a sequence from
the 3′ region called miR-142-3p) and were likely
to affect messenger RNA (mRNA) target specificity (Fig. S5A in the Supplementary Appendix). The
expression of miR-142-3p and miR-142-5p (a sequence from the 5′ region) is thought to be restricted primarily to the hematopoietic compartment.21,22 Data from miRNA sequencing showed
that miR-142 was highly expressed in AML samples (Fig. S5B in the Supplementary Appendix).
The mutated miR-142 alleles were expressed at levels similar to those of the nonmutated allele in
all samples (Fig. S5C in the Supplementary Appendix). Although miR-142 mutations have not
previously been identified, several reports have
linked aberrant expression of miR-142-3p with
hematologic cancers, including precursor B-cell23
and T-cell24,25 acute lymphoblastic leukemia and
AML.26 The remaining mutations in miRNA
genes were localized to precursor miRNAs (in
3 samples) or to a nonseed region of a mature
miRNA (in 1 sample).
n engl j med 368;22

We identified all the variants predicted to cause
mRNA truncation that were found in both the
skin and tumor samples (see the Results section,
Table S11, and Fig. S6 in the Supplementary Appendix). However, very few of the genes with
truncation variants were found to be expressed
in most AML samples (including the samples carrying the variants themselves), suggesting that
most of the inherited truncating variants were
probably irrelevant for pathogenesis.
Functional Categorization of Mutated Genes
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Figure 2 (facing page). Organization of Mutations
into Categories of Related Genes.
Shown are somatic, nonsynonymous mutations in individual genes and sets of genes, grouped into nine
categories, including one single-gene category, as labeled on the left. Of the 200 samples evaluated, 199
(>99%) had at least one mutation in one of the listed
genes or sets. Blue boxes indicate mutations that are
exclusive across all categories; green boxes, mutations
that co-occur in the same sample across different categories; and orange boxes, mutations that co-occur in
the same sample in the same category. Computational
analysis with the use of the Dendrix++ algorithm identified three significant, mutually exclusive groups of
genes, annotated on the right as groups A, B, and C.
The cytogenetic risk for each patient is shown at the
bottom of the chart. Additional information about data
in this figure is provided in Tables S17 through S20 in
the Supplementary Appendix. Ser–Thr denotes serine–
threonine, TF transcription factor, and Tyr tyrosine.

is extremely small (P<6.3×10−7 for NPM1 and
DNMT3A and P<1.9×10−6 for NPM1 and FLT3).
This observation, combined with the strong association between samples having concurrent
mutations in NPM1, FLT3, and DNMT3A and distinct clusters in mRNA, miRNA, and DNA
methylation, suggests that samples with mutations in all three genes represent a novel subtype
of AML. Furthermore, we observed relationships
of strong mutual exclusivity. For example, PMLRARA, MYH11-CBFB, and MLL-containing fusion
genes were mutually exclusive of mutations in
NPM1 and DNMT3A (P<0.007, P<0.04, and P<0.04,
respectively), and RUNX1 and TP53 mutations were
mutually exclusive of FLT3 and NPM1 mutations.
Table S12 in the Supplementary Appendix contains
a full list of genes or gene sets with significant
co-occurrences or exclusivity among the samples.
Gene Fusions

sivity and co-occurrence between sets of genes,
we applied Dendrix++ (see the Materials section
in the Supplementary Appendix) to the mutation
matrix. Dendrix++ identified three sets of genes
with the strongest patterns of mutual exclusivity
(groups A, B, and C) (Fig. 2). The most statistically significant set included the transcriptionfactor fusion genes, NPM1, RUNX1, TP53, and
CEBPA (Fig. S10 in the Supplementary Appendix).
The second most significant set showed exclusivity between mutations in FLT3 and in genes encoding other tyrosine kinases, serine–threonine
kinases, protein tyrosine phosphatases, and RAS
family proteins (Fig. S9 in the Supplementary
Appendix). The third set included mutations in
ASXL1 and in genes encoding components of the
cohesin complex, other myeloid transcription factors, and other epigenetic modifiers (Fig. S10 in
the Supplementary Appendix). Mutations within
the spliceosome gene set, genes encoding other
epigenetic modifiers, and genes encoding myeloid
transcription factors also showed considerable
mutual exclusivity within each set (Fig. S11 in the
Supplementary Appendix).
Among the pairwise relationships between mutations in the AML samples, the most prominent
was the significant co-occurrence between mutations in FLT3, DNMT3A, and NPM1 (Fig. S8 in the
Supplementary Appendix). In particular, many
samples had mutations both in NPM1 and
DNMT3A or in NPM1 and FLT3. The likelihood
that these mutations occurred together by chance
n engl j med 368;22

De novo assembly of RNA-sequencing data28 for
179 AML samples identified 118 gene fusions
in 80 samples (mean, 1.5 per sample), of which
71 were distinct events (Fig. 3A)29; 99 samples
had no detected fusions (Table S13 in the Supplementary Appendix). The range of fusions per sample was 0 to 8. The 74 in-frame fusions included
many previously described, recurrent events, including PML-RARA, MYH11-CBFB, RUNX1-RUNX1T1,
BCR-ABL1, PICALM-MLLT10/AF10, NUP98-NSD1, and
multiple fusions involving MLL (Fig. 3B). We identified 15 new fusion events that maintained an
open reading frame. Although none of them were
recurrent in this cohort, several of the genes in
the fusions were mutated or translocated in other
samples of AML that we analyzed (i.e., MLLT10/
AF10, NF1, GRID1, PPP2R1B, XIAP, ATP1B4, WSB1,
KIAA0999, TBX15, and LRRC37B). An additional
42 gene fusions were out-of-frame (Fig. 3C), creating a truncated upstream gene or potential
haploinsufficiency for both partner genes, with
many that were mutated or translocated in other
AML samples (including RUNX1, DNMT3B, MLLT10/
AF10, NSD1, EDIL3, SCARB1, XIAP1, PPP2R1B, FOXP1,
KSR2, MLL3, and CUL1). One out-of-frame fusion
(GAS6-FAM70B) was detected in three AML samples, and one of its fusion partners (FAM70B
P233L) was mutated in another sample. Most of
the newly described fusion events in these samples were not detected by means of routine cytogenetic studies (Table S1 in the Supplementary
Appendix).
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Figure 3. AML Gene Fusions.
Panel A is a plot created with the use of Circos software29 showing in-frame (green) and out-of-frame (orange) gene fusions
detected in the AML cohort in the Cancer Genome Atlas (TCGA) with the use of Trans-ABySS software.28 Ribbon widths
are proportional to the frequency of a fusion event. Chromosomes are individually colored and are arranged clockwise
from chromosome 1 to X, starting with chromosome 1 at 12 o’clock. No rearrangements involved the Y chromosome. The
frequencies of in-frame and out-of-frame gene fusions are shown in Panels B and C, respectively. For gene names shown
in red, one of the partner genes in that fusion was found to be mutated in at least one other AML sample from this data
set. On the basis of chromosomal aberrations and genomic variants annotated in the Mitelman database from the Cancer
Genome Anatomy Project (CGAP) (http://cgap.nci.nih.gov/Chromosomes/Mitelman), all previously identified gene fusions are shown in blue, a single known polymorphic fusion is shown in green, and all novel events are shown in red.
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Figure 4. Unsupervised RNA and miRNA Expression Patterns.
Shown are unsupervised consensus clusters for data obtained with the use of messenger RNA sequencing (Panel A) and microRNA
(miRNA) sequencing (Panel B). Shown from top to bottom are RNA abundance heatmaps, with each messenger RNA or miRNA centered on its mean; atypical members of each group (shown in black), which have silhouette widths below 0.9 of the group’s maximum
width; a silhouette-width profile (i.e., a dimensionless metric that reflects how well samples fit into compact and distinct clusters) that
was calculated from the consensus membership matrix; and covariates (e.g., FAB subtypes), with P values for association corrected for
multiple testing, at the far left and far right (see the Methods section in the Supplementary Appendix). B-H denotes Benjamini–Hochberg
multiple-testing correction. The numbers refer to the silhouette-width profiles for which P values are provided. One asterisk denotes
P<0.05, two asterisks P<0.01, and three asterisks P<0.001. The color scales for both heatmaps reflect mean-normalized log2 abundances,
with RPKM (reads per kilobase of exon model per million mapped reads) for RNA-sequencing data and log2 RPM (reads per million) for
miRNA-sequencing data. The scale-bar numbers (−2.5 for least abundant to 2.5 for most abundant) indicate the range of log2 mean-centered abundance values in the heatmaps. Cytogenetic-risk profiles are shown at the bottom of the chart.

Gene-Expression Analysis

abundance information) suggested an optimum of
Unsupervised non-negative matrix factorization seven RNA-sequencing groups and five miRNA(NMF) consensus clustering (i.e., clustering data sequencing groups (Fig. S12 in the Supplementary
with inputs consisting only of gene or miRNA Appendix). Associations between these groups
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Figure 5 (facing page). Unsupervised Analysis of DNA
Methylation at Extremes of CpG Density.
DNA-methylation values for specific CpG residues are
shown as a proportion, ranging from 0% (unmethylated,
in blue) to 100% (fully methylated, in red), for unsupervised clustering of CpG-dense regions of the genome
(Panel A) and of CpG-sparse regions (Panel B). Covariates are shown below the corresponding samples. Data
for CD34+CD38− bone marrow cells, promyelocytes,
neutrophils, and monocytes from three healthy volunteers are plotted to the left of the data for 192 AML
samples in each panel. CpG islands and shores are annotated in dark green and light green, respectively, in
the space between the normal and AML samples. CpG
density was computed as the ratio of observed to expected CG dinucleotides in a 3-kb window, as described by
Saxonov et al.36 The 1000 most variable loci among
those falling into the top and bottom 5% according to
CpG density are plotted in Panels A and B, respectively.
Cytogenetic-risk profiles are shown at the bottom of
the chart.

and overall survival are shown in Fig. S13 in the
Supplementary Appendix; the groups enriched
for samples containing PML-RARA had better
outcomes than other groups, as expected. The
RNA-sequencing groups were highly concordant
with a microarray data set for the same 178 samples (Fig. S14 in the Supplementary Appendix).
We used one-sided Fisher’s exact tests (corrected for multiple testing) to identify significant
associations (P<0.05) between specific RNAsequencing and miRNA-sequencing groups and
covariates (Fig. 4). RNA-sequencing group 4 was
associated with subtype M1 (AML with minimal
maturation) in the French–American–British (FAB)
classification of acute leukemias, group 3 with
FAB subtype M3 (acute promyelocytic leukemia),
group 5 with FAB subtype M4 (acute myelomonocytic leukemia), and group 7 with FAB subtype
M5 (acute monoblastic or monocytic leukemia)
(Fig. 4A). Concordance between gene-expression
groups and FAB subtypes was similar to that
previously reported for microarray data30,31 and
showed that some expression signatures were
strongly correlated with the stage of myeloid differentiation of the AML sample.
For the miRNA-sequencing data, group 5 was
associated with FAB subtype M3, and groups 2,
3, and 5 were associated with unfavorable, intermediate, and favorable cytogenetic risk categories,
respectively. Group 3 was strongly associated with
mutations in NPM1, DNMT3A, FLT3, and genes
encoding the cohesin complex; miR-10a was exn engl j med 368;22

pressed at high levels in this group, an observation that is consistent with reports correlating high
miR-10a expression and NPM1 mutations32,33
(Fig. 4B). Levels of miR-424 were relatively low
in this group, making miR-424 the second-most
discriminatory miRNA — an observation that is
consistent with the findings in a previous study.34
The data also confirmed that miR-196b, miR-130a,
and let-7b were discriminatory in this group.35
Additional comparisons with published sets of
expression data are provided in the Materials
section in the Supplementary Appendix.
DNA-Methylation Analysis

Unsupervised analysis of changes in DNA methylation revealed significant differences among subsets of samples, particularly in CpG-sparse regions of the genome (Fig. 5).36 Samples with
IDH1 and IDH2 mutations showed extensive gains
of methylation relative to CD34+CD38− cells obtained from healthy donors (Table S14 in the
Supplementary Appendix), whereas some samples
with MLL fusions or co-occurring NPM1, DNMT3A,
and FLT3 mutations were associated with extensive loss of DNA methylation, as compared with
normal CD34+CD38− cells. Specific patterns of
methylation gain and loss distinguished samples
with CEBPA mutations, as well as samples with
PML-RARA, RUNX1-RUNX1T1, or MYH11-CBFB fusions. Significant changes in DNA methylation
were identified across AML samples at 160,519
CpG loci (42% of sites tested), with 67% resulting in a gain of methylation and 33% resulting in
a loss (see the Methods section and Table S15 in
the Supplementary Appendix). Samples with
triple mutations in NPM1, DNMT3A, and FLT3
showed methylation losses at 328 of 382 differentially methylated regions larger than 1 kb
(86%), as compared with CD34+CD38− cells
from healthy donors. Although both intergenic
and genic regions were affected, approximately
71% of these changes were in coding regions
(Table S16 in the Supplementary Appendix).
We also assessed the relationships between
gene expression and DNA methylation in pairs
of data types by identifying groups in one data
type that were enriched in samples from a group
in the other data type (Fig. S15A through S15E in
the Supplementary Appendix). Clusters containing samples of acute promyelocytic leukemia were
strongly concordant for mRNA, miRNA, and
CpG-sparse DNA methylation (Fig. 5, and Fig.
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S15 in the Supplementary Appendix). In mRNA
groups 1, 2, 5, and 6, there was a preferential
association with one miRNA-sequencing group
each, suggesting that regulatory relationships must
exist between these groups (Fig. S15A in the
Supplementary Appendix). Associations in CpGsparse DNA methylation groups were more significant for miRNA groups than for mRNA
groups, suggesting the existence of previously
unrecognized epigenetic regulatory pathways (Fig.
S15B through S15E in the Supplementary Appendix). Genes defining the RNA- and miRNAsequencing groups are shown in Figure S16 in
the Supplementary Appendix; a very striking set
of small RNA genes within an imprinted locus on
chromosome 14 were found to be consistently
dysregulated in acute promyelocytic leukemia
(Fig. S17 in the Supplementary Appendix).37

Discussion
Of the adult cancer types that have been extensively sequenced to date, AML has had the fewest
mutations discovered (Fig. S18 in the Supplementary Appendix). The average number of coding
mutations (SNVs and indels) per patient in this
study was 13, of which only 5 were recurrently
mutated in each genome. There was little evidence of genomic instability in most AML genomes. However, a small number of patients had
an unfavorable-risk (complex) cytogenetic profile
that was strongly associated with mutations in
TP53, which confirmed a recently reported relationship.38 Adult AML genomes contain a median of only one somatic copy-number variant and an
average of less than one gene-fusion event (generally caused by translocations).1,2
The organization of mutated genes into nine
functionally related categories revealed many
potentially important biologic relationships. The
transcription-factor fusions were the first recognized somatic mutations in AML genomes,1,2 and
all such fusions have been shown to be relevant
for disease initiation in mice.39-42 Our data show
that some mutations that are common in AML
(e.g., in DNMT3A, NPM1, CEPBA, IDH1/2, and RUNX1)
are mutually exclusive of the transcription-factor
fusions, suggesting that these mutations may have
functions in the initiation of AML that are similar
to the functions of fusion genes. We also identified a pattern of mutual exclusivity for mutations
in genes within certain biologic classes, including
2072
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those encoding the cohesins, proteins of the splice
osome, signaling proteins, and histone-modifying
proteins, suggesting that one mutation in these
pathways is generally adequate for AML pathogenesis. Although a common model of AML pathogenesis has suggested that an activating mutation in a gene encoding a signaling protein might
be a requirement for pathogenesis,43 only 59% of
the patients in our study had a mutation in a
gene annotated to suggest a role in signaling.
We integrated the expression data for both
mRNA and miRNA with all the clinical and mutational data for all genomes. That analysis revealed that the differentiation state of the AML
sample was highly correlated with the expression signature, as reported previously.44 Patients
who had PML-RARA fusions had very distinct
mRNA and miRNA signatures that were strongly
correlated with each other and with a specific DNA
methylation signature.45 All the transcriptionfactor fusions were correlated with specific patterns of mRNA expression, whereas PML-RARA
and RUNX1-RUNX1T1 (and some MLL fusions) were
also associated with miRNA expression signatures.
In addition, occurrence of NPM1, DNMT3A, and
FLT3 mutations together was strongly associated
with specific expression signatures for both
mRNA and miRNA. These data suggest that this
combination of mutations in patients with intermediate-risk AML may identify a subtype of AML
with unique epigenetic features. Our analysis of
methylation patterns corroborates previous reports of methylation signatures in CpG islands for
transcription-factor fusions and IDH1/2 mutations46,47 but surprisingly revealed that the strongest methylation signatures occur in CpG-sparse
regions of the genome. Although the significance of this finding is not yet clear, the widespread and variable losses of methylation in
these regions are consistent with observations
from analyses of epithelial tumors48 and support
the idea that methylation patterns in gene bodies and intergenic regions are important for the
regulation of gene expression.49
This data set will be available to provide a
framework for future studies that pertain to the
molecular classification of patients with AML.
The identification of many potentially important
relationships among recurrently mutated AML
genes and pathways provides a comprehensive
foundation for an understanding of the genetic
rules of pathogenesis.
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